Moreover, high expression of NONO or c-Myc was correlated with poor survival of patients with adrenocortical carcinoma, bladder cancer, breast cancer, colon cancer, esophagus cancer, glioblastoma, lung cancer, ovarian cancer, or renal cancer (Additional file 1: Fig. S8). Here, MYC is linked to ovarian cancer.